StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3049% below fair value
$149.40−7.10 (-4.54%)

Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –

Alnylam Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Alnylam Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $5.01B, up 56.2% year over year. For fiscal 2025 it was $3.71B, up 65.2% from the year before. Over ten years it grew 43.5% a year on average. The highest annual figure on record is $3.71B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.71B+65.2%
FY2024Dec 31, 2024$2.25B+23.0%
FY2023Dec 31, 2023$1.83B+76.2%
FY2022Dec 31, 2022$1.04B+22.9%
FY2021Dec 31, 2021$844.29M+71.3%
FY2020Dec 31, 2020$492.85M+124.3%
FY2019Dec 31, 2019$219.75M+193.4%
FY2018Dec 31, 2018$74.91M-16.7%
FY2017Dec 31, 2017$89.91M+90.7%
FY2016Dec 31, 2016$47.16M-52.9%
FY2010Dec 31, 2010$100.04M-0.5%
FY2009Dec 31, 2009$100.53M+4.5%
FY2008Dec 31, 2008$96.16M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.46B+16.7%
Q2 FY2026Jun 30, 2026$1.29B+66.9%
Q1 FY2026Mar 31, 2026$1.17B+96.4%
Q4 FY2025Dec 31, 2025$1.10B+84.9%
Q3 FY2025Sep 30, 2025$1.25B+149.3%
Q2 FY2025Jun 30, 2025$773.69M+17.3%
Q1 FY2025Mar 31, 2025$594.19M+20.2%
Q4 FY2024Dec 31, 2024$593.17M+34.9%
Q3 FY2024Sep 30, 2024$500.92M-33.3%
Q2 FY2024Jun 30, 2024$659.83M+107.0%
Q1 FY2024Mar 31, 2024$494.33M+54.8%
Q4 FY2023Dec 31, 2023$439.72M+31.2%
Q3 FY2023Sep 30, 2023$750.53M+184.0%
Q2 FY2023Jun 30, 2023$318.75M+41.8%
Q1 FY2023Mar 31, 2023$319.29M+49.7%
Q4 FY2022Dec 31, 2022$335.04M+29.6%
Q3 FY2022Sep 30, 2022$264.31M+40.9%
Q2 FY2022Jun 30, 2022$224.82M+1.9%
Q1 FY2022Mar 31, 2022$213.26M+20.1%
Q4 FY2021Dec 31, 2021$258.54M+58.1%
Q3 FY2021Sep 30, 2021$187.63M+49.1%
Q2 FY2021Jun 30, 2021$220.55M+112.1%
Q1 FY2021Mar 31, 2021$177.57M+78.5%
Q4 FY2020Dec 31, 2020$163.56M+128.2%
Q3 FY2020Sep 30, 2020$125.85M+79.6%
Q2 FY2020Jun 30, 2020$103.96M+132.5%
Q1 FY2020Mar 31, 2020$99.48M+198.8%
Q4 FY2019Dec 31, 2019$71.68M+240.8%
Q3 FY2019Sep 30, 2019$70.06M+3286.2%
Q2 FY2019Jun 30, 2019$44.71M+49.5%
Q1 FY2019Mar 31, 2019$33.29M+52.0%
Q4 FY2018Dec 31, 2018$21.03M-44.5%
Q3 FY2018Sep 30, 2018$2.07M-87.9%
Q2 FY2018Jun 30, 2018$29.91M+87.7%
Q1 FY2018Mar 31, 2018$21.90M+15.5%
Q4 FY2017Dec 31, 2017$37.92M–
Q3 FY2017Sep 30, 2017$17.10M–
Q2 FY2017Jun 30, 2017$15.93M–
Q1 FY2017Mar 31, 2017$18.96M–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?